- •Preface to the Second Edition
- •Contents
- •List of Abbreviations
- •1: Epidemiology of AMD
- •Core Messages
- •1.1 Introduction
- •1.3 Frequency
- •1.3.1 Prevalence
- •1.3.2 Incidence
- •1.4 Natural Course
- •1.5 Genetic Factors
- •1.5.1 The Complement Pathway Genes
- •1.5.1.1 Complement Factor H (CFH)
- •1.5.1.3 Complement Component 3 (C3)
- •1.5.1.4 Complement Factor I (CFI)
- •1.5.2 The ARMS2 (10q26) Locus
- •1.5.3.1 Apolipoprotein E (APOE)
- •1.5.4 Candidate Gene Association Studies
- •1.6 Environmental Factors
- •1.6.1 Smoking
- •1.6.2 Antioxidants
- •1.6.3 Body Mass Index (BMI)
- •1.6.4 Hypertension
- •1.6.5 Cataract Surgery
- •1.7 Interaction Between Risk Determinants
- •1.7.1 Combined Effects of CFH Y402H and Other Genetic and/or Environmental Factors
- •1.7.2 Combined Effects of 10q26 SNPs and Other Genetic and/or Environmental Factors
- •1.7.4 Combined Effects of the APOE Gene and Other Genetic and/or Environmental Factors
- •References
- •2: Genetics
- •Core Messages
- •2.1 Introduction
- •2.2 Identifying Risk Factors of a Common Disease
- •2.3 Early Findings
- •2.4.1 Functional Implications
- •2.5.1 Functional Implications
- •2.7 Prospects of Genetics in AMD Therapy and Prevention
- •Summary for the Clinician
- •References
- •Core Messages
- •3.1 Introduction
- •3.2 Cause and Consequences of Ageing
- •3.3 Clinical Changes Associated with Retinal Ageing
- •3.4 Ageing of the Neural Retina
- •3.5 Ageing of the RPE
- •3.5.1 Changes in RPE Cell Density
- •3.5.2 Subcellular Changes in the RPE
- •3.5.3 Accumulation of Lipofuscin
- •3.5.4 Melanosomes and Pigment Complexes
- •3.5.7 Antioxidant Capacity of the RPE
- •3.6 Ageing of Bruch’s Membrane
- •3.7 The Association Between Ageing and AMD
- •Summary for the Clinician
- •References
- •Core Messages
- •4.1 Introduction
- •4.2 The Complement System
- •4.3 Evidence for Involvement of the Complement System in AMD Pathogenesis
- •4.4.2 Complement Gene Variants and AMD Subtypes
- •4.4.3 Complement Gene Variants and Progression of AMD
- •4.4.5 Variations of Complement Genes and Response to Treatment: Pharmacogenetics
- •4.5 Emerging Pharmacological Intervention Targeting Complement Dysregulation
- •Conclusions
- •Summary for the Clinician
- •References
- •5: Histopathology
- •Core Messages
- •5.1 Retinal Pigment Epithelium
- •5.1.1 Structure and Function of the Retinal Pigment Epithelium
- •5.1.3 Deposits in the RPE
- •5.2 Bruch’s Membrane
- •5.2.1 Structure of Bruch’s Membrane
- •5.2.3 Deposits in Bruch’s Membrane, Drusen
- •5.3 Choroidal Neovascularization
- •5.4 Detachment of the Retinal Pigment Epithelium
- •5.5 Geographic Atrophy of the RPE
- •Summary for the Clinician
- •References
- •6: Early AMD
- •Core Messages
- •6.1 Introduction
- •6.2 Drusen
- •6.2.3 Fluorescence Angiography and Optical Coherence Tomography
- •6.3 Focal Hypopigmentation and Hyperpigmentation of the Retinal Pigment Epithelium
- •6.4 Abnormal Choroidal Perfusion
- •Summary for the Clinician
- •References
- •Core Messages
- •7.1 Introduction
- •7.2.1 Decreased Visual Acuity
- •7.2.2 Visual Distortion
- •7.2.3 Visual Field Defects
- •7.2.4 Miscellaneous Symptoms
- •7.3 Signs of Choroidal Neovascularization
- •7.3.1 Hemorrhage
- •7.3.2 Macular Edema and Subretinal Fluid
- •7.3.3 Retinal Pigment Epithelial Detachment
- •7.3.4 Miscellaneous Signs
- •7.4 Common Testing Modalities to Diagnose Choroidal Neovascularization
- •7.4.1 Fluorescein Angiography
- •7.4.2 Indocyanine Green Angiography
- •7.4.4 Optical Coherence Tomography
- •Summary for the Clinician
- •References
- •8: Geographic Atrophy
- •Core Messages
- •8.1 Introduction
- •8.3 Histology and Pathogenesis of Geographic Atrophy
- •8.5 Spectral Domain Optical Coherence Tomography in Geographic Atrophy
- •8.7 Risk Factors
- •8.7.1 Genetic Factors
- •8.7.2 Systemic Risk Factors
- •8.7.3 Ocular Risk Factors
- •8.8 Development of CNV in Eyes with GA
- •8.9 Visual Function in GA Patients
- •8.9.1 Measurement of Visual Acuity
- •8.9.2 Contrast Sensitivity
- •8.9.3 Reading Speed
- •8.9.4 Fundus Perimetry
- •8.10 Perspectives for Therapeutic Interventions
- •8.10.2 Complement Inhibition
- •8.10.3 Neuroprotection
- •8.10.4 Alleviation of Oxidative Stress
- •8.10.5 Serotonin-1A-Agonist
- •8.10.6 Perspective
- •Summary for the Clinician
- •References
- •9: Fundus Imaging of AMD
- •Core Messages
- •9.1 Introduction
- •9.2 Color Photography
- •9.3 Monochromatic Photography
- •9.5 Optical Coherence Tomography
- •9.5.2 Coherence Length
- •9.5.3 Time Domain Optical Coherence Tomography
- •9.5.4 Frequency Domain Optical Coherence Tomography
- •9.5.5 Increasing Depth of Imaging
- •9.5.6 General Optical Coherence Tomographic Imaging Characteristics of the Macular Region
- •9.6 Fundus Angiography
- •9.6.1 Fluorescein Dye Characteristics
- •9.6.2 Indocyanine Green Dye Characteristics
- •9.6.3 Cameras Used in Fluorescence Angiography
- •9.6.4 Patient Consent and Instruction
- •9.6.5 Fluorescein Injection
- •9.6.6 Fluorescein Technique
- •9.6.7 Indocyanine Green Technique
- •9.7 Fluorescein Angiographic Interpretation
- •9.7.1 Filling Sequence
- •9.7.2 The Macula
- •9.8 Deviations from Normal Angiographic Appearance
- •9.10.1 Drusen
- •9.12 Neovascular AMD
- •9.13 Retinal Pigment Epithelial Detachments
- •9.14 Retinal Vascular Contribution to the Exudative Process
- •9.15 Follow-up
- •9.15.1 Thermal Laser
- •9.15.2 Photodynamic Therapy
- •9.15.3 Anti-VEGF Therapy
- •Summary for the Clinician
- •References
- •10: Optical Coherence Tomography
- •10.1 Introduction
- •Core Messages
- •10.4 OCT in Geographic Atrophy
- •10.5 OCT in Exudative AMD
- •Summary for Clinician
- •References
- •11: Microperimetry
- •Core Messages
- •11.1 Introduction
- •11.2.1 From Manual to Automatic Microperimetry
- •11.2.2 Automatic Microperimetry
- •11.2.3 Microperimetry: The Examination
- •11.2.4 Microperimetry: Test Evaluation
- •11.2.5 Other Microperimeter
- •11.3 Microperimetry in AMD
- •11.3.1 Early AMD
- •11.3.2 Geographic Atrophy
- •11.3.3 Neovascular AMD
- •11.3.4 Neovascular AMD: Treatment
- •Summary for the Clinician
- •References
- •Core Messages
- •12.1 Introduction
- •12.2 Antioxidants and Zinc
- •12.3 Beta-Carotene
- •12.4 Macular Xanthophylls
- •12.6 Vitamin E
- •12.7 Vitamin C
- •12.8 Zinc
- •12.10 AREDS2
- •Summary for the Clinician
- •References
- •Core Messages
- •13.1 Introduction
- •13.2 Basic Principles
- •13.2.1 Clinical Background
- •13.2.2 Laser Photocoagulation
- •13.2.3 Photodynamic Therapy
- •13.3 Treatment Procedures
- •13.3.1 Laser Photocoagulation
- •13.3.2 Photodynamic Therapy
- •13.4 Study Results
- •13.4.1 Laser Photocoagulation
- •13.4.1.1 Extrafoveal CNV
- •13.4.1.2 Subfoveal CNV
- •13.4.1.3 Meta-analysis
- •13.4.2 Photodynamic Therapy
- •13.4.2.1 Predominantly Classic
- •13.4.2.2 Occult with No Classic Neovascularization
- •13.4.2.3 Minimally Classic
- •13.5 Safety and Adverse Events
- •13.5.1 Laser Photocoagulation
- •13.5.2 Photodynamic Therapy
- •13.6 Variations
- •13.6.1 Laser Photocoagulation: Different Wavelengths
- •13.6.2 Photodynamic Therapy
- •13.6.3 Combination Treatments
- •13.7 Present Guidelines
- •13.7.1 Laser Photocoagulation
- •13.7.2 Photodynamic Therapy
- •13.8 Perspectives
- •Summary for the Clinician
- •References
- •Core Messages
- •14.1 Introduction
- •14.2 Vascular Endothelial Growth Factor (VEGF)
- •14.3 Targets Within the VEGF Pathway
- •14.3.1 Sequestration of Released VEGF
- •14.3.2 Inhibition of VEGF and VEGF Receptor Synthesis by Small Interfering RNA (siRNA)
- •14.3.3 Inhibition of the Intracellular Signal Cascade
- •14.3.4 Natural VEGF Inhibitors
- •14.4 New Methods of Drug Delivery
- •14.5 Combined Strategies
- •Summary for the Clinician
- •References
- •Core Messages
- •15.1 Introduction
- •15.1.1 Anti-VEGF Therapies for NV-AMD
- •15.2.1 How Should Neovascular AMD be Diagnosed?
- •15.2.4.1 Results with Continuous Monthly Treatment
- •15.2.4.2 How Should Treatment be Started?
- •15.2.4.3 What Flexible Approaches Are Reported?
- •Fixed Quarterly Injection Studies
- •Flexible Dosing Regimens: Two Approaches
- •Flexible Dosing Regimens: ‘As Needed’ Approach
- •Flexible Dosing Regimens: ‘Treat-and-Extend’ Approach
- •Summary for the Clinician
- •References
- •Core Messages
- •16.1 Introduction
- •16.3 Current Limitation of Therapy in the Treatment of Exudative AMD
- •16.4 Rationale for Combination Therapy in the Treatment of Exudative AMD
- •16.5 Clinical Data Examining Combination Therapy for Exudative AMD
- •16.5.3 Triple Therapy for Exudative AMD
- •16.5.4 Combination Therapy with Radiation
- •Summary for the Clinician
- •References
- •Core Messages
- •17.1 Introduction
- •17.2 Current Treatment Options for Dry AMD
- •17.3 Targeting the Cause of AMD
- •17.4 Preclinical and Phase I Drugs in Development for Dry AMD
- •17.4.1 Clinical Trial Endpoints in Dry AMD
- •Trimetazidine
- •17.4.2.2 Neuroprotection
- •Ciliary Neurotrophic Factor (CNTF/NT-501)
- •AL-8309B (Tandospirone)
- •Brimonidine Tartrate Intravitreal Implant
- •17.4.2.3 Visual Cycle Modulators
- •Fenretinide
- •17.4.2.4 Other
- •17.4.3 Drugs to Prevent Injury from Oxidative Stress and Micronutrient Depletion
- •17.4.4.1 Complement Inhibition at C3
- •17.4.4.2 Complement Inhibition at C5
- •Eculizumab
- •17.4.4.3 Complement Inhibition of Factor D
- •FCFD4514S
- •Iluvien
- •Glatiramer Acetate (Copaxone)
- •17.5 Summary
- •Summary for the Clinician
- •References
- •18: Surgical Therapy
- •Core Messages
- •18.1 Maculoplasty
- •18.2 Macular Translocation
- •18.3 Single Cell Suspensions
- •18.5 Indications for Surgery
- •18.5.1 Non-responder
- •18.5.2 Pigment Epithelium Rupture
- •18.5.3 Massive Submacular Bleeding
- •18.5.5 Macula Dystrophies
- •Summary for the Clinician
- •References
- •19: Reading with AMD
- •Core Messages
- •19.1 Introduction
- •19.2 Physiological Principles
- •19.3 Reading with a Central Scotoma
- •19.3.1.2 The Reading Visual Field Related to the Fundus (Fig. 19.4b)
- •19.3.1.3 The Reading Visual Field Related to the Text (Fig. 19.4c)
- •19.3.1.4 Eccentric Fixation Related to the Globe (Fig. 19.5)
- •19.3.3 Examination of Fixation Behaviour
- •19.3.4 Motor Aspects
- •19.4 Methods to Examine Reading Ability
- •19.5 Rehabilitation Approaches to Improve Reading Ability
- •Summary for the Clinician
- •References
- •20: Low Vision Aids in AMD
- •Core Messages
- •20.2 Effects of Visual Impairment in AMD
- •20.5 Optical Magnifying Visual Aids for Distance
- •20.5.1 Aids for Watching Television
- •20.8 Electronic Reading Instruments
- •20.9 Additional Aids
- •20.10 Noteworthy Details for the Provision of Low Vision Aids
- •20.11 Basic Information on Prescription
- •Summary for the Clinician
- •References
- •Index
19 Reading with AMD |
291 |
|
|
a |
22–81 % |
b |
|
|
|
|
|
0–11 % |
0–20 % 4–63 %
0–7 %
Fig. 19.6 Direction of scotoma shift: (a). Summarized results of several studies: mostly the scotoma is shifted upwards or to the right, i.e. fixation is below or left of the scotoma [12–15] (b). On the retina the eccentric retinal fixation loci are accordingly located mostly above or left of the lesion, i.e. in the left upper quadrant in both eyes [12]
Table 19.2 Clinical assessment of fixation
•Gaze direction: corneal reflexes
•Perimetry: localization of the blind spot
•Fundus image: fixation of a fixation target in direct ophthalmoscopy
•By means of the corneal reflexes the gaze direction can be assessed at a glance. When the patient is asked to fixate the eyes of the investigator, the patients views to the hairline for example (Fig. 19.5 bottom right).
•By perimetry: The position of the blind spot indicates the fixation behaviour. Eccentric fixation can be diagnosed by a thorough perimetry. In a manual perimetry, the shift of the blind spot can be shown clearly Fig. 19.4a. In an automated perimetry, the blind spot can be ‘lacking’ (due to the shift). A shift can only be proven with a dense test-point grid. In case of alternating PRLs, the blind spot sometimes can be shown in 2 different locations.
•At the fundus the fixation locus can be determined using the fixation star in the direct ophthalmoscope.
19.3.4 Motor Aspects
Fig. 19.7 SLO-fundus image of a patient with AMD: she reads the text with an eccentric retinal locus above the lesion. She is fixating the ‘i’. The patient sees the text upright. The movement of the fovea along the text can be recorded in the SLO-video
stage of the disease, when the central seeing island has disappeared and eccentric fixation becomes possible. ‘Eccentric viewing training’ can be helpful in such cases [19].
Some patients are able to change their fixation locus depending on the task: They fixate small stimuli, such as single optotypes, centrally, but broad stimuli, such as words, eccentrically. They are able to read with the corresponding magnification. Thus, these patients show a discrepancy between visual acuity and magnification need [12].
19.3.3 Examination of Fixation Behaviour
Fixation behaviour can often be diagnosed with easy methods (Table 19.2):
Fixation stability plays an important role for eccentric reading. Unstable fixation is unfavourable [20].
Eye movements during reading show impaired reading patterns in patients with AMD as a consequence of their sensory deficit. In patients with early macular degeneration, the reading pattern is preserved in principle, reading speed is reduced, the number of forward saccades is increased. In patients with advanced macular degeneration, the reading pattern is no longer regular. Reading speed is markedly decreased, the number of forward and backward saccades markedly increased [6, 21].
19.4Methods to Examine Reading Ability
1.Refractive error, accommodation range, visual acuity for far and near: These are necessary as a basis for later adaption of visual aids.
2.Magnification need: A simple and valuable method to examine the potential reading ability in a patient with foveal vision loss is the determination of
292 |
S. Trauzettel-Klosinski |
|
|
Fig. 19.8 For determination of parafoveal contrast sensitivity the macular mapping test [24] can be used. This test consists of a recognition task in the 8° visual field (radius) at different positions and contrast levels. Left: A wagon-wheel serves as a fixation target. The letters have to be recognized. Right: the result shows the recognized stimuli (white), detected but not recognized stimuli (grey), as well as not detected stimuli (black). The test is suited for a subtle monitoring of the course and can be helpful for early detection of AMD [25]
magnification need. Special reading charts for lowvision patients (e.g. MN-Read charts) provide texts in different magnifications compared to normal newspaper print. In a defined distance, the magnification need can be determined directly. This test does not only tell, if magnification is helpful at all, but also what amount is necessary. This is the basis for the selection and application of a magnifying visual aid.
3.Reading speed: Reading speed should be measured with standardized paragraphs of text to be read aloud. Paragraphs instead of single sentences are preferable for a more accurate measurement of speed. Reading aloud provides additional information about fluency, mistakes and understanding. Newly developed texts in 17 languages are available: ten equivalent texts in each language for repeated measurements, all of them were elaborated for equal length, difficulty and linguistic complexity (International Reading Speed Texts, IReST, http://www.amd-read.net) [22, 23]. This evidence-based method allows a standardized documentation of the success during treatment and rehabilitation interventions.
4.Parafoveal contrast sensitivity (Fig. 19.8): It can be easily and quickly tested by the Macular Mapping Test [24] with different contrast levels. It is suitable for monitoring the course of the AMD, for assessing treatment effects and can be helpful for early detection [25].
5.Central visual field: Visual field defects in the centre, i.e. involving the reading visual field, cause reading impairment. Additionally, the position of the blind spot provides information about fixation behaviour.
6.Fixation behaviour: Knowledge about fixation behaviour (central or eccentric) is important in cases of
discrepancies between good visual acuity and reading disability as in ring scotoma.
7.Eye movement recording: Recording of eye movements during reading provides additional information about the reading strategy, especially for scientific investigations [6, 21].
19.5Rehabilitation Approaches to Improve Reading Ability
The aim of rehabilitation is optimization of residual function and support of compensatory processes (Table 19.3). For improving reading ability a wide pallet of magnifying visual aids is available (see Chap. 20 and Table 19.4). In an own study of 835 AMD patients an improvement of reading speed occurred in 94% of the patients. The mean improvement was 45 words per minute (Fig. 19.9) [26, 27].
Another crucial measure is training to handle the visual aids.
Additionally, reading speed can be further improved by specific reading training with computer training programs, as we showed in a randomized and controlled study in patients with central scotoma due to juvenile maculopathy Stargardt [28]. The patients could improve their reading speed by additional 20 words per minute and they were also able to apply their newly learned strategy in everyday life during page reading.
Regarding ‘eccentric viewing training’ positive results have been reported [19], but there is still considerable controversy about methods and criteria for choosing the optimal area [29].
19 Reading with AMD |
293 |
|
|
Table 19.3 Rehabilitation: aims
•Optimization of the residual function
•Reading and orientation ability
•Independence, mental agility, quality of life
Table 19.4 Rehabilitation measures for reading disorders
Visual aids (see Chap. 20)
•Magnifying, contrast enhancing
•Illumination
Training
•Handling of the visual aids (crucial!)
•Specific reading training; sensory and motor (recommendable)
•Use of the best fixation locus: ‘eccentric viewing training’ (controversial)
Social counselling
aids |
300 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
250 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of visual |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
afterspeedadaptation |
(words/minute) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reading |
50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
N = 835 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0 |
50 |
100 |
150 |
200 |
250 |
300 |
|||||||||||||||
Reading speed before adaptation of visual aids (words/minute)
Fig. 19.9 Reading speed before adaptation of magnifying aids in words per minute (abscissa) compared to the reading speed after adaptation of visual aids (ordinate) in 835 AMD patients. An improvement occurred in 94% of the patients with an average increase of 45 words per minute (Modified after [26, 27])
Table 19.5 Conclusions: preconditions for reading ability in AMD
Sensory
•Sufficient size of the reading visual field and sufficient resolution of the retinal area used for reading. In eccentric fixation, the insufficient resolution can be compensated by magnification of the text.
Motor
•Stable fixation and regular reading eye movements
General
•Motivation
•Cognitive ability
•Manual skills
Summary for the Clinician
›Loss of reading ability is the most serious functional impact in AMD.
›The preconditions for reading ability in patients with AMD are concerned with three areas (Table 19.5):
›Sensory: A sufficient size of the reading visual field and a sufficient resolution of the retinal area used are necessary. In eccentric fixation, the insufficient resolution can be compensated by text magnification.
›Motor: Stable fixation and regular reading eye movements are favourable.
›General: The motivation of the patient and his cognitive abilities are of importance. Additionally, manual skills play a role for handling the visual aids and computer software programs.
›For examination of reading ability standardized tests are available. The determination of visual acuity is not sufficient as this measures only recognizing one optotype at a time. The knowledge of the central visual field and the fixation locus are especially important in patients with a ring scotoma, who show a discrepancy between good visual acuity and high magnification need. Determination of magnification requirement is crucial for further rehabilitation measures. Assessment of reading speed with standardized texts allows a quantitative and evidence-based procedure for diagnostics, monitoring the course and for documentation of success after treatment and rehabilitative interventions.
›RehabilitationisverysuccessfulinAMDandallows an improvement of reading ability in most patients.
294 |
S. Trauzettel-Klosinski |
|
|
References
1. Knauer C, Pfeiffer N (2006) Erblindung in Deutschland – heute und 2030. Ophthalmologe 103:735–741
2.Nguyen NX, Weismann M, Trauzettel-Klosinski S (2008) Ophthalmologische und soziale Rehabilitation sehbehinderter Patienten: Eine retrospektive Analyse an der Tübinger Sehbehindertenambulanz im Zeitraum von 1999 bis 2005. Ophthalmologe 105:563–569
3.Trauzettel-Klosinski S, Nguyen NX (2008) Steigender Bedarf an ophthalmologischer Rehabilitation. Augenspiegel 1:32–35
4.Trauzettel-Klosinski S (2010) Rehabilitation for visual
disorders. JNO 30:73–84
5. Horton HC, Hoyt WF (1991) The representation of the visual field in human striate cortex: a revision of the classic Holmes map. Arch Ophthalmol 109:816–824
6. Trauzettel-Klosinski S, Teschner C, Tornow RP, Zrenner E (1994) Reading strategies in normal subjects and in patients with macular scotoma - assessed by two new methods of registration. Neuroophthalmology 14:15–30
7. Wertheim T (1894) Über die indirekte Sehschärfe. Z Psychol 7:172–187
8.AulhornE(1953)ÜberFixationsbreiteundFixationsfrequenz beim Lesen gerichteter Konturen. Pflügers Arch Physiol 257:318–328
9.Legge GE, Ahn SJ, Klitz TS, Luebker A (1997) Psychphysics of reading – XVI. The visual span in normal and low vision. Vision Res 37:1999–2010
10. Rayner K (1986) Eye movements and the perceptual span in beginning and skilled readers. J Exp Child Psychol 41: 211–236
11. McConkie GW, Rayner K (1975) The span of the effective stimulus during a fixation in reading. Percept Psychophys 17:578–586
12. Trauzettel-Klosinski S, Tornow RP (1996) Fixation behaviour and reading in macular scotoma – assessed by Tuebingen Manual Perimetry and SLO. Neuroophthalmology 16: 241–253
13. Fletcher D, Schuchard R (1997) Preferred retinal loci: relationship to macular scotomas in a low vision population. Ophthalmology 104:632–638
14. Guez J-E, Le Gargasson J-F, Rigaudiere F, O’Regan JK (1993) Is there a systematic location for the pseudo – fovea in patients with central scotoma? Vision Res 33:1271–1279
15. Messias A, Reinhard J, Cruz A, Dietz K, MacKeben M, Trauzettel-Klosinski S (2007) Eccentric fixation in Stargardt’s disease – assessed by Tuebingen Perimetry. Invest Ophthalmol Vis Sci 48(12):5815–5822
16.Aulhorn E (1975) Die Gesichtsfeldprüfung bei makularen Erkrankungen. In: Ber. 73. Zusammenk. der DOG Heidelberg 1973. JF Bergmann, München, pp 77–86
17.Altpeter E, Mackeben M, Trauzettel-Klosinski S (2000) The importance of sustained attention for patients with maculopathies. Vision Res 40:1539–1547
18.Mackeben M (2009) The role of focal sustained attention in macular scotoma. Neuroophthalmology 33(3): 127–131
19.Nilsson UL, Frennesson C, Nilsson SEG (2003) Patients
with AMD and a large absolute scotoma can be trained successfully to use eccentric viewing as demonstrated in a scanning laser ophthalmoscope. Vision Res 43:1777–1787
20. Crossland MD, Culham LE, Rubin GS (2004) Fixation stability and reading speed in patients with newly developed macular disease. Ophthal Physiol Opt 24:327–333
21. Rubin G, Feely M (2009) The role of eye movements during reading in patients with age-related macular degneration (AMD). Neuroophthalmology 33:120–126
22. Hahn GA, Penka D, Gehrlich C, Messias A, Weismann M, Hyvärinen L, Leinonen M, Feely M, Rubin G, Dauxerre C, Vital-Durand F, Featherston S, Dietz K, Trauzettel-Klosinski S (2006) New standardised texts for assessing reading performance in four European languages. Br J Ophthalmol 90:480–484
23. Trauzettel-Klosinski S, Dietz K and the IReST study group (2011) Standardized assessment of reading performance: the new International Reading Speed Texts IReST. IOVS in review.
24. Mackeben M, Colenbrander A, Gofen A (1999) Use your PC to quickly map remaining vision after foveal vision loss. In: Wild JM, Wall M (Hrsg.) (eds) Perimetry update 1998/1999. Kugler, Amsterdam, pp 307–316
25. Hahn GA, Messias A, MacKeben M, Dietz K, Horwath K, Hyvärinen L, Leinonen M, Trauzettel-Klosinski S (2009) Parafoveal letter recognition at reduced contrast in normal aging and in patients with risk factors for AMD. Graefes Arch Clin Exp Ophthalmol 247(1):43–51
26.Nguyen NX, Trauzettel-Klosinski S (2009) Effectiveness of low vision aids on reading ability in patients with age-related macular degeneration. Neuroophthalmology 33(3):115–119
27.Nguyen NX, Weismann M, Trauzettel-Klosinski S (2009) Improvement of reading speed after providing of low vision aids in patients with age-related macular degeneration. Acta Ophthalmol 87:849–853
28.Nguyen NX, Stockum A, Hahn GA, Trauzettel-Klosinski S (2009) Training to improve reading speed in patients with juvenile macular dystrophy: a randomized controlled study.
Acta Ophthalmol 33:115–119
29. Stelmack JA, Massof RW, Stelmack TR (2004) Is there a standard of care for eccentric viewing training ? J Rehabil Res Dev 41:729–738
